R21/Matrix-M

Phase 3Biologic

UUniversity of Oxford

R21/Matrix-M is one of 21 biologic programs targeting Malaria. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MalariaActive, not recruiting

MalariaPhase 3

Active, not recruiting

Competition

Competitive Landscape

479 competitors in Malaria

#DrugCompanyPhaseTrials

R21/Matrix-M

UUniversity of Oxford

Phase 3

4 2

Biltricide

Bayer

Preclinical

1 3

Stelara

Johnson & Johnson

Preclinical

—4

Hydroxychloroquine Sulfate

Novartis

Preclinical

—5

Iron

WWatson Pharmaceuticals

Preclinical

1 6

IV LBH589

Novartis

Preclinical

1 7

Mefloquine Plus Artesunate

Medicines for Malaria Venture

Preclinical

1 8

IV Ceftriaxone

RRESnTEC, Institute of Research

Preclinical

1 9

RTS,S/AS01E

GSK

Preclinical

4 10

Malarone

Medicines for Malaria Venture

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Active, not recruiting

Malaria

NCT04704830

Clinical

Trials by Indication[1]

Malaria4 trials

Safety and Immunogenicity of the Malaria Vaccine, R21/MatrixM, in Healthy Thai Adults

Completed·UUniversity of Oxford·Phase 2·NCT05252845·127 enrolled

Seasonal R21 Mass Vaccination for Malaria Elimination

Recruiting·LLondon School of Hygiene and Tropical Medicine·Phase 3·NCT06578572·16,200 enrolled

R21/Matrix-M in African Children Against Clinical Malaria

Active, not recruiting·UUniversity of Oxford·Phase 3·NCT04704830·4,800 enrolled

Show 1 more trial

A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan Adults

Terminated·UUniversity of Oxford·Phase 2·NCT03947190·80 enrolled

Immunogenicity2 trials

Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration With EPI Vaccines

Completed·UUniversity of Oxford·Phase 1·NCT05155579·593 enrolled

Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV

Completed·UUniversity of Oxford·Phase 1·NCT05385510·122 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for R21/Matrix-M. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R21/Matrix-M compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R21/Matrix-M. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Oxford company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: UUniversity of Oxford

R21/Matrix-M

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Malaria4 trials

Immunogenicity2 trials

References

Drug Info

Quick Facts

Related News